VERO Biotech

VERO Biotech is an innovative biotechnology company dedicated to addressing the unmet medical needs of patients with cardiopulmonary conditions. For healthcare providers and their most vulnerable patients, particularly neonates with hypoxic respiratory failure, the challenges of managing traditional inhaled nitric oxide (iNO) therapy are significant. Cumbersome, high-pressure gas tanks create logistical hurdles, increase the risk of complications, and can disrupt the seamless delivery of care. Recognizing these critical issues, VERO Biotech has pioneered a transformative solution to improve the lives of patients and the workflow of clinicians who serve them.

Our core mission is centered on the patient and the provider. We developed GENOSYL® DS, the first and only tankless inhaled nitric oxide (iNO) delivery system approved by the FDA. This groundbreaking technology was designed to directly alleviate the burdens associated with conventional iNO systems. Instead of relying on bulky tanks, GENOSYL® DS generates nitric oxide on-demand at the patient's bedside using small, disposable cassettes. This innovation not only simplifies the entire process of care but also enhances safety by minimizing the potential for exposure to nitrogen dioxide (NO2). Our customers in the neonatal intensive care unit (NICU) and other acute care settings can now experience a more streamlined, efficient, and reliable method of iNO administration. This allows them to focus more on direct patient care and less on managing equipment, ultimately leading to better patient outcomes and a less stressful environment for everyone involved. We are committed to the continuous development of our technology to provide solutions that meet the evolving challenges faced by the healthcare community.